Syncona Limited


Rated Fund 2016-17, 2020. Backs potential global leaders in life sciences

This specialist healthcare investment trust was recommended on interactive investor’s ACE 30 list of ethical investments in 2019 and was the third most-bought ethical fund on the platform last year. It was removed from our Rated Funds in 2017 because its shares were trading at a premium, but it returns for 2020.

Its shares have significantly de-rated over the past 12 months – more so than other trusts in the biotechnology and healthcare sector – from a near 46% premium to single digits. We like the trust for its focus on unquoted companies, which are best held through a closed-ended structure, and it replaces International Biotechnology, which includes some big biotech names.

Syncona is a FTSE 250-listed company focused on founding, building and funding global leaders in innovative areas of life science, and is an established leader in cell and gene therapies. It is managed by a team with deep scientific backgrounds and strong commercial experience. Chief executive Martin Murphy co-founded Syncona (originally BACIT) in 2012 with the Wellcome Trust. He was previously a partner at MVM Life Science Partners, a venture capital company focused on life science and healthcare.

The trust taps into rising global demand for healthcare, fuelled by ageing global populations, increased knowledge and awareness among patients and the growing prevalence of chronic diseases. It takes significant ownership stakes in companies with the potential to be global leaders in areas of high unmet need that it can own at least to commercialisation. The portfolio is made up of no more than 15-20 companies that can deliver transformational treatments to patients.

Narrative and ratings content all as of January 2020.

See all Money Observer rated funds
Syncona Limited
Syncona Investment Management Limited
Closed Ended Investment Company
Sector Specialist: Biotechnology & Healthcare
1.82 %
3 Year Sharpe
0 %
Fund Size
£ 1.69 billion
Discount Premium
The investment objective is to deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes. The Company will target an IRR per share across its investment portfolio of 15% p.a. over the long term. Over time, it is intended that the Company should invest the significant majority of its assets in Life Science Investments.
Syncona Investment Management Limited
NW1 2BE, London, United Kingdom
Legal Structure
Closed Ended Investment Company


Tom Henderson
Joined 10/26/2012
Arabella Cecil
Joined 10/26/2012
John McDonald
Joined 10/26/2012

McDonald has been a vice president and associate portfolio manager with Phoenix Investment Counsel since 1992. He joined the company in 1990 as a marketing coordinator for investment communications, and became a research analyst in 1991. McDonald began his career in 1989 as a financial services advisor for The America Group. McDonald earned his Chartered Financial Analyst designation in 1994. He was born November 29, 1967 in Waterbury, Connecticut.

Data provided by Morningstar.

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Money Observer and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Morningstar. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.